Eli Lilly's new weight-loss injection, retatrutide, has demonstrated significant results in a Phase 3 trial, with patients losing an average of 28.3% of their body weight. Nearly half of participants on the highest dose achieved weight loss equivalent to bariatric surgery, a result that has boosted Lilly's stock.